Tilsotolimod with Ipilimumab Drives Tumor Responses in Anti-PD-1 Refractory Melanoma

Many patients with advanced melanoma are resistant to immune checkpoint inhibition. In the ILLUMINATE-204 phase I/II trial, we assessed intratumoral tilsotolimod, an investigational Toll-like receptor 9 agonist, with systemic ipilimumab in patients with anti-PD-1- resistant advanced melanoma. In all...

Full description

Saved in:
Bibliographic Details
Published in:Cancer discovery 2021-08, Vol.11 (8), p.1996-2013
Main Authors: Haymaker, Cara, Johnson, Daniel H, Murthy, Ravi, Bentebibel, Salah-Eddine, Uemura, Marc I, Hudgens, Courtney W, Safa, Houssein, James, Marihella, Andtbacka, Robert H I, Johnson, Douglas B, Shaheen, Montaser, Davies, Michael A, Rahimian, Shah, Chunduru, Srinivas K, Milton, Denái R, Tetzlaff, Michael T, Overwijk, Willem W, Hwu, Patrick, Gabrail, Nashat, Agrawal, Sudhir, Doolittle, Gary, Puzanov, Igor, Markowitz, Joseph, Bernatchez, Chantale, Diab, Adi
Format: Article
Language:English
Subjects:
Adult
Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols
Female
Humans
Immune Checkpoint Inhibitors - administration & dosage
Immune Checkpoint Inhibitors - therapeutic use
Ipilimumab - administration & dosage
Ipilimumab - therapeutic use
Male
Melanoma - drug therapy
Middle Aged
Skin Neoplasms - drug therapy
Treatment Outcome
United States
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Many patients with advanced melanoma are resistant to immune checkpoint inhibition. In the ILLUMINATE-204 phase I/II trial, we assessed intratumoral tilsotolimod, an investigational Toll-like receptor 9 agonist, with systemic ipilimumab in patients with anti-PD-1- resistant advanced melanoma. In all patients, 48.4% experienced grade 3/4 treatment-emergent adverse events. The overall response rate at the recommended phase II dose of 8 mg was 22.4%, and an additional 49% of patients had stable disease. Responses in noninjected lesions and in patients expected to be resistant to ipilimumab monotherapy were observed. Rapid induction of a local IFNα gene signature, dendritic cell maturation and enhanced markers of antigen presentation, and T-cell clonal expansion correlated with clinical response. A phase III clinical trial with this combination (NCT03445533) is ongoing. SIGNIFICANCE: Despite recent developments in advanced melanoma therapies, most patients do not experience durable responses. Intratumoral tilsotolimod injection elicits a rapid, local type 1 IFN response and, in combination with ipilimumab, activates T cells to promote clinical activity, including in distant lesions and patients not expected to respond to ipilimumab alone. .
ISSN:2159-8274
2159-8290
DOI:10.1158/2159-8290.CD-20-1546